AA
CLDX icon

ALPS Advisors’s Celldex Therapeutics CLDX Stock Holding History

ALPS Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.95M Buy
79,165
+24,975
+46% +$807K 0.01% 408
2026
Q1 		$1.72M Sell
54,190
-369
-0.7% -$10.1K 0.01% 433
2025
Q4 		$1.48M Buy
54,559
+22,643
+71% +$596K 0.01% 458
2025
Q3 		$826K Sell
31,916
-3,896
-11% -$90.3K ﹤0.01% 590
2025
Q2 		$729K Sell
35,812
-14,126
-28% -$275K ﹤0.01% 579
2025
Q1 		$906K Sell
49,938
-3,712
-7% -$82.9K 0.01% 485
2024
Q4 		$1.36M Buy
53,650
+2,993
+6% +$81.3K 0.01% 410
2024
Q3 		$1.72M Sell
50,657
-742
-1% -$28.3K 0.01% 383
2024
Q2 		$1.9M Buy
51,399
+5,959
+13% +$225K 0.01% 346
2024
Q1 		$1.91M Buy
45,440
+7,795
+21% +$320K 0.01% 359
2023
Q4 		$1.49M Buy
37,645
+2,797
+8% +$82.3K 0.01% 383
2023
Q3 		$959K Buy
34,848
+113
+0.3% +$3.54K 0.01% 465
2023
Q2 		$1.18M Buy
34,735
+3,630
+12% +$122K 0.01% 437
2023
Q1 		$1.12M Sell
31,105
-844
-3% -$36.4K 0.01% 446
2022
Q4 		$1.42M Buy
31,949
+6,389
+25% +$228K 0.01% 368
2022
Q3 		$718K Sell
25,560
-2,180
-8% -$66.8K 0.01% 536
2022
Q2 		$748K Buy
+27,740
New +$806K 0.01% 517
2021
Q2 		– Sell
-71,581
Closed -$1.48M – 906
2021
Q1 		$1.48M Buy
71,581
+861
+1% +$19.8K 0.01% 353
2020
Q4 		$1.24M Buy
+70,720
New +$1.27M 0.01% 366
2017
Q2 		– Sell
-7,013
Closed -$380K – 773
2017
Q1 		$380K Buy
7,013
+526
+8% +$27.4K ﹤0.01% 671
2016
Q4 		$344K Sell
6,487
-2,058
-24% -$117K ﹤0.01% 655
2016
Q3 		$518K Sell
8,545
-700
-8% -$43.6K ﹤0.01% 265
2016
Q2 		$609K Buy
9,245
+1,845
+25% +$117K 0.01% 229
2016
Q1 		$420K Sell
7,400
-1,263
-15% -$142K ﹤0.01% 531
2015
Q4 		$2.04M Sell
8,663
-1,613
-16% -$352K 0.02% 177
2015
Q3 		$1.62M Buy
10,276
+3,761
+58% +$1.06M 0.02% 183
2015
Q2 		$2.46M Buy
6,515
+3,305
+103% +$1.31M 0.02% 152
2015
Q1 		$1.34M Buy
+3,210
New +$1.15M 0.01% 170

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ALPS Advisors's CLDX Position: Q2 2026 in Review

ALPS Advisors increased its Celldex Therapeutics (CLDX) stake by 46% in Q2 2026, buying an estimated $807K and bringing the position to 79,165 shares worth $2.95M. The position accounts for 0.01% of the portfolio, ranked #408.

ALPS Advisors first reported a position in CLDX in Q1 2015 and has held it in 28 quarters since. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • ALPS Advisors held 79,165 shares of Celldex Therapeutics worth $2.95M as of Q2 2026.
  • ALPS Advisors bought 24,975 Celldex Therapeutics shares in Q2 2026, an estimated $807K.
  • Celldex Therapeutics made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #408 holding.
  • ALPS Advisors first reported a position in Celldex Therapeutics in Q1 2015 and has held it in 28 quarters since.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.